Abstract. Possible arterio-venous gradients of T4, T3, rT3 and 3,3'-diiodothyronine (3,3'-T2) across the liver and the kidneys were measured in 9 patients with varying degrees of liver failure undergoing diagnostic catheterization. Plasma iodothyronine levels were measured in peripheral, hepatic and renal veins before and at 10-min intervals until 60 min after iv injection of 400 \ of TRH. In 2 patients estimated hepatic plasma flow and effective renal plasma flow were determined as well. In these 2 patients, no significant differences between iodothyronine levels in arterial and peripheral venous plasma were found. T4 and T3 levels were not significantly different between peripheral, renal and hepatic veins. Hepatic vein rT3 and 3,3'-T2 concentrations were 10.7 \ m=+-\8.3% (mean \m=+-\ SD, P < 0.005) and 36 \m=+-\18% (P < 0.001) lower than those in the peripheral vein (N = 9). Renal vein rT3 was just (6.2 \m=+-\7.5%, P < 0.05) lower than rT3 in peripheral vein, whereas 3,3'-T2 was not different between the two veins. Estimates of hepatic and renal plasma flow were in agreement with values from the literature. On the basis of these data approximate hepatic clearance rates of 110 and 380 1/day for rT3 and 3,3'-T2 and a renal clearance rate of about 35 1/day for rT3 were calculated. Sixty min after TRH, plasma T3 was increased to 147 \m=+-\56% (P < 0.05) and 3,3'-T2 in peripheral plasma was increased to 142 \ m=+-\36% (P < 0.025), whereas plasma T4 and rT3 did not change. These data suggest that the liver is the major site of plasma rT3 and 3,3'-T2 clearance in patients with mild liver disease and probably also in healthy humans. The kidneys may account for roughly 25% of plasma rT3 clearance. The increase in plasma 3,3'-T2 after TRH may be secondary to the rise in precursor T3, but thyroidal secretion of 3,3'-T2 is not excluded.
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It is generally believed that T4 is the main secre¬ tory product of the thyroid, and that other iodo¬ thyronines are produced predominantly by se¬ quential deiodination of T4 in peripheral tissues (Engler & Burger 1984; Hennemann 1986) . By phenolic or outer ring deiodination T4 is con¬ verted to T3, whereas rT3 is generated by tyrosyl or inner ring deiodination of T4. Both T3 and rT3 are subject to further deiodination to 3,3'-diiodothyronine (3,3'-T2) . Of all iodothyronines only T3 has significant intrinsic bioactivity.
Recent studies in rats have demonstrated at least three different types of iodothyronine-deiodinating enzymes (Kaplan 1984; Hesch & Koehrle 1986; Leonard & Visser 1986 ). The type I deiodinase is most abundant in the liver, kidney and thyroid and is inhibited by propylthiouracil (PTU) . Type I deiodination of T4 in the liver and kidney is a major pathway of peripheral T3 pro¬ duction in normal rats (Silva et al. 1984 (Leonard & Visser 1986 (Kaplan 1984; Leonard & Visser 1986 (Roti et al. 1983; Kaplan 1984; Huang et al. 1985 Visser et al. 1983) . Extensive sulphation and glucuronidation of iodothyronines have been observed in isolated liver cells (Sorimachi & Robbins 1977; Otten et al. 1983 ), but considerable extrahepatic conjugation occurs in dogs (Bollman & Flock 1965 (Visser et al. 1977 (Visser et al. , 1978 . Coefficients of variation were 4, 6, 5 and 7% within assays, and 5, 7, 7 and 7% between assays, respectively.
In patients Nos. 7 and 8, estimated hepatic plasma flow (EHPF) and effective renal plasma flow (ERPF) measurements were made during hepatic and renal vein catheterization. EHPF was determined using indocyanine green (Leevy et al. 1962 ) and ERPF with 131I-hippuran (Donker et al. 1977 ). (Fig. 1) .
No statistically significant difference between the means of the arterial and peripheral vein 3,3'-T2 levels measured 0-60 min after TRH administration could be established in the 2 pa¬ tients studied (Table 3) (Fig. 1) .
In patients Nos. 7 and 8, EHPF amounted to estimates of the metabolic clearance rates of these compounds in normal subjects, i.e. 82-151 and 560-1120 1/day, respectively (Hennemann 1986 ). The mean ERPF in patient Nos. 7 and 8 was 396 ml/min which is also considered normal (Donker et al. 1977) . In combination with the mean 6.2% decrease of plasma rT3 over the kidney in the whole patient group, this suggests that the renal clearance of rT3 is approximately 35 1/day, i.e. roughly one-quarter of the total metabolic clear¬ ance rate.
The data presented here are in agreement with Downloaded from Bioscientifica.com at 10/24/2018 04:13:00AM via free access the report of Faber et al. (1980) reported to enhance T3 production from T4 in both isolated perfused rat liver and kidney (Ikeda et al. 1985 (Ikeda et al. , 1986 (Leonard & Visser 1986 ). However, further degradation of rT3 by outer ring deiodination to 3,3'-T2 is almost three orders of magnitude more effective than its production from T4 (Leonard & Visser 1986 ). In rat hepatocytes, 3,3'-T2 is rapidly metabolized by successive sulphation and type I deiodination of the outer ring ). The high rate of 3,3'-T2 sulphation explains why little 3,3'-T2 formation is observed if rT3 is incubated with rat hepatocytes (Eelkman Rooda et al. 1987 ). These findings suggest that rT3 and 3,3'-T2 produced in the human liver are further metabolized before being released into the circulation. Type I deio¬ dination of T3 in the liver is slow unless the hormone is sulphated. This yields 3,3'-T2 sulphate and not free 3,3'-T2 as a transient intermediate Visser et al. 1983) . It is likely, therefore, that in humans, plasma rT3 and 3,3'-T2 are mainly of extra-hepatic origin, where they are possibly produced by type III inner ring deio¬ dination of T4 and T3, respectively (Kaplan 1984; Leonard & Visser 1986 ). This view is supported by the findings that a) 85% of circulating 3,3'-T2 is derived from inner ring deiodination of T3 (Engler & Burger 1984) and b) production of plasma rT3 is much less affected by PTU than the metab¬ olic clearance of this compound (Laurberg & Weeke 1980) . The increase in plasma 3,3'-T2 in our subjects in response to TRH was similar in magnitude and in onset to the increase in plasma T3. These results are in contrast with the lack of effect of TRH Downloaded from Bioscientifica.com at 10/24/2018 04:13:00AM via free access administration on plasma 3,3'-T2 in humans as reported by Burman et al. (1977) , although these workers noted a TRH-induced increase in plasma 3,3'-T2 in sheep. It is excluded that the increase in plasma 3,3'-T2 immunoreactivity in our patients is due to cross-reactivity of T3 in the 3,3'-T2 RIA (Visser et al. 1978 ). In conclusion, the present findings indicate that the liver is the major site for the clearance but not the production of plasma rT3 and 3,3'-T2, where¬ as some rT3 may also be cleared by the kidneys.
